DSAM Partners’s Iovance Biotherapeutics IOVA Stock Holding History

DSAM Partners’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-81,627	Closed	-$2.12M	–	33
2021 Q2	$2.12M	Hold	81,627	–	–	0.36%	35
2021 Q1	$2.58M	Sell	81,627 -20,530	-20%	-$851K	0.48%	37
2020 Q4	$4.74M	Buy	+102,157	New	+$4.06M	0.55%	48

Other funds holding IOVA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

DSAM Partners's IOVA Position: Q3 2021 in Review

DSAM Partners sold out of Iovance Biotherapeutics (IOVA) in Q3 2021, closing a stake of 81,627 shares — an estimated $2.12M sold.

DSAM Partners first reported a position in IOVA in Q4 2020 and held it in 3 quarters. The position peaked at $4.74M in Q4 2020. 243 funds tracked by Wall St. Rank hold IOVA as of Q3 2021.

DSAM Partners reported no remaining Iovance Biotherapeutics position as of Q3 2021 after selling out during the quarter.
DSAM Partners sold 81,627 Iovance Biotherapeutics shares in Q3 2021, an estimated $2.12M.
DSAM Partners first reported a position in Iovance Biotherapeutics in Q4 2020 and held it in 3 quarters.
DSAM Partners's Iovance Biotherapeutics position peaked at $4.74M in Q4 2020.
243 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2021.

Based on DSAM Partners's 13F filing for Q3 2021, filed 15 Nov 2021.